Skip to main content

Week in Review: James Watson to Lead New Shenzhen Biopharma Research Center

Industry Developments James Watson, who co-discovered the structure of DNA in 1953, will lead a new international life science research center in Shenzhen's International Bio Valley that plans to hire more than 1,000 scientists; Deals and Financings Oxford Nanopore, a UK company that offers portable real-time DNA/RNA sequencers, completed a $140 million funding led by Asian investors; TCR 2 Therapeutics, an Boston immunoncology company, closed a $125 million Series B financing co-led by 6 Dimension Capital, a Boston-Shanghai investor; CASI Pharma, a Maryland-Beijing company, announced a $50 million private placement to launch its first commercial product in China ; Infervision of Beijing raised $47 million in a B+ round to support its AI-aided CT cancer scanning software; Akonni Biosystems of Maryland and China 's Righton announced a two-way diagnostic products commercial agreement; Fosun Pharma acquired China rights to an thrombocytopenia candidate from US-based Dova Pharma; Senju Pharma of Osaka in-licensed China and Japan rights to a potential treatment for diabetic macular edema from Montreal 's SemaThera; Trials and Approvals   Japan 's Chugai Pharma reported the CFDA accepted its New Drug Application for eldecalcitol, an oral active vitamin D3 derivative for osteoporosis; Avita Medical of Melbourne started a China clinical trial of ReCell® to treat second-degree burns using autologous cells; Company News Cellular Biomedicine will develop its stem cell and CAR-T projects exclusively in China , closing down its California operations; Government and Regulatory   As part of an initiative to open its economy to other countries, China plans to eliminate the small tariffs on some imported drugs, especially those for cancer. Stock Symbols: (NSDQ: CASI) (SHA: 600196; HK: 02196) (NSDQ: DOVA) (TYO: 4519) (ASX: AVH; OTCQX: AVMXY) (NSDQ: CBMG) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.